Evidence Hub

Efficacy of Inhaled Colistin in Critically Ill Children with Ventilator-Associated Pneumonia Resistant to Multiple Drugs

G. Khanbabaee, Maryam Mirjafari, Azita Behzad, Seyedeh Masumeh Hashemi, Seyedeh Narjes Ahmadizadeh, Maryam Alemzadeh, Bahador Mirrahimi

Journal of Comprehensive Pediatrics, 2024

80 participants · 1 citation

Abstract

Background: Ventilator-associated pneumonia (VAP) is the leading cause of death related to mechanical ventilation and the most common nosocomial infection in the intensive care unit (ICU). Objectives: This study aimed to investigate the efficacy of adjunctive inhaled colistin in critically ill children with multidrug-resistant ventilator-associated pneumonia (MDR-VAP). Methods: In this prospective cohort study, 80 critically ill patients aged 2 to 18 years with MDR-VAP were admitted to the PICU of Mofid Children's Hospital in Tehran between 2019 and the end of 2022. Eligible patients were divided into two equal groups: The colistin group (receiving inhaled colistin in addition to other antibiotics) and the control group (receiving only intravenous antibiotics). Clinical and laboratory findings were compared between the two groups. Results: The mean ages of participants in the control and colistin groups were 21.2 ± 2.9 and 24.9 ± 1.7 months, respectively (P = 0.51). The duration of hospital stay in the colistin group was 34.92 ± 20.03 days, compared to 29.83 ± 22.35 days in the control group, which was not statistically significant (P = 0.29). The duration of mechanical ventilation use was similar between the control group (23.15 ± 21.17 days) and the colistin group (24.06 ± 17.87 days) (P = 0.83). Mortality rates were also comparable, with 65% in the control group and 57.5% in the colistin group (P = 0.49). Conclusions: Inhaled colistin did not significantly reduce the…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 80 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free